中国癫痫:过去二十年的重大进展
WHO全球抗癫痫运动中国项目证实在基层医疗中治疗癫痫可行,中国抗癫痫协会推动了 care 与研究兴趣,目前近20种抗癫痫药物可用。
要点
- 基层医疗可治疗癫痫,WHO项目证实可行
- 近20种抗癫痫药物可用,但管理仍有未满足需求
核心结论
- 中国癫痫诊疗取得重大进展,但公共健康和减少不平等仍是主要挑战。
研究设计与样本
- 综述性文章,总结中国过去二十年癫痫诊疗进展。
主要发现
- 治疗缺口主要源于医疗服务不足和文化信仰导致的社会歧视。
- WHO全球抗癫痫运动中国项目证实在基层医疗中治疗癫痫可行。
- 中国抗癫痫协会推动了医学界对癫痫诊疗和研究的兴趣。
- 中国目前有近20种抗癫痫药物可用,非药物选择也存在,但管理仍有未满足需求。
临床怎么用
- 在基层医疗中可开展癫痫治疗。
- 利用多种抗癫痫药物和非药物选项管理癫痫。
局限性
- 原文未讨论具体研究设计或样本量等局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
China has approximately 10 million people with epilepsy. There is a vast epilepsy treatment gap in China, mainly driven by deficiencies in health-care delivery and social discrimination resulting from cultural beliefs about epilepsy. WHO's Global Campaign Against Epilepsy project in China showed that it was possible to treat epilepsy in primary care settings, which was a notable milestone. The China Association Against Epilepsy has been a necessary force to stimulate interest in epilepsy care and research by the medical and scientific community. Nearly 20 different anti-seizure medications are now available in China. Non-pharmacological options are also available, but there are still unmet needs for epilepsy management. The Chinese epilepsy research portfolio is varied, but the areas in which there are the most concentrated focus and expertise are epidemiology and clinical research. The challenges for further improvement in delivering care for people with epilepsy in China are primarily related to public health and reducing inequalities within this vast country.
引用
- Ding D, Zhou D, Sander JW, et al. Epilepsy in China: major progress in the past two decades. Lancet Neurol. 2021. PMID: 33743240. doi:10.1016/S1474-4422(21)00023-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。